
Combination Drug Delivery Approach as an Effective Therapy for Various Diseases
- 1st Edition - March 27, 2022
- Editor: Prashant Kesharwani
- Language: English
- Paperback ISBN:9 7 8 - 0 - 3 2 3 - 8 5 8 7 3 - 1
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 8 5 8 7 6 - 2
Combination Drug Delivery Approach as an Effective Therapy for Various Diseases explores the use of bioengineering tools in combination drug delivery approaches to control v… Read more

Purchase options

Institutional subscription on ScienceDirect
Request a sales quoteCombination Drug Delivery Approach as an Effective Therapy for Various Diseases explores the use of bioengineering tools in combination drug delivery approaches to control various diseases at different clinical stages of synergistic action, varying mechanisms of action, and during the suppression of drug resistance. The book presents fundamental knowledge on the experiential and experimental aspects of drug combination approaches in order to equip rational applications in preventing the emergence of resistance during the treatment of various diseases. It provides a holistic understanding of the principles behind formation, characterization, applications, regulations, toxicity, challenges and future perspectives of combination drug delivery approaches.
It will be of interest to researchers and advanced graduate students in pharmaceutical science, chemistry, biology and medicine, as well as pharmaceutical companies and scientific organizations.
- Provides an accounting of vital aspects on various combination drug delivery approaches, presenting next generation diagnostics and therapeutics
- Discusses the perspectives of current technologies in highly organized tables, illustrative figures and flow charts
- Defines major gaps in knowledge that can lead to significant scientific discoveries
- Cover image
- Title page
- Table of Contents
- Copyright
- Dedication
- List of contributors
- Preface
- Acknowledgments
- Part A: Combination drug delivery approaches against various diseases
- Chapter 1. Overcoming cancer drug resistance via nanomedicine-based combined drug delivery
- Abstract
- 1.1 Introduction
- 1.2 Organic nanocarriers
- 1.3 Inorganic nanocarriers
- 1.4 Conclusion
- References
- Chapter 2. Overcoming the challenges of drug resistance through combination drug delivery approach
- Abstract
- 2.1 Introduction
- 2.2 Drug resistance in cancer
- 2.3 Combination drug delivery approach to overcome antimicrobial resistance
- 2.4 Conclusion
- References
- Chapter 3. Combination drug delivery approaches in ophthalmology
- Abstract
- 3.1 The eye
- 3.2 The need for new ophthalmic treatments
- 3.3 Drug–device combinations in ophthalmology
- 3.4 Challenges and future perspectives
- References
- Chapter 4. Combination drug delivery system to enhance the transdermal drug delivery of bioactive molecules
- Abstract
- 4.1 Introduction
- 4.2 Physiological skin row versus percutaneous permeation of bioactive molecules
- 4.3 Strategies used to enhance transdermal transport
- 4.4 Physical parameters of permeability of lipid vesicles
- 4.5 Conclusions
- Acknowledgments
- References
- Chapter 5. Combination drug delivery approaches in rheumatoid arthritis
- Abstract
- 5.1 Introduction
- 5.2 Nanoparticles for rheumatoid arthritis therapy
- 5.3 siRNA and miRNA for rheumatoid arthritis therapy
- 5.4 Combinatory therapy for gene and drug delivery
- 5.5 Challenges and future perspectives
- 5.6 Conclusion
- Disclosures
- Acknowledgments
- References
- Chapter 6. Aptamer-mediated drug delivery system for cardiovascular diseases
- Abstract
- 6.1 Introduction
- 6.2 Conventional drug delivery systems for cardiovascular diseases
- 6.3 Aptameric drug delivery systems for cardiovascular diseases
- 6.4 Future perspective
- 6.5 Conclusion
- References
- Chapter 7. Combination drug delivery approaches for viral infections
- Abstract
- 7.1 Introduction
- 7.2 Combination drug therapy to counter various viral infections
- 7.3 Approach and scope of improvement of combination drug therapy to treat viral infections
- 7.4 Conclusion and future perspective
- Acknowledgments
- References
- Chapter 8. Approaches and molecular tools for targeted drug delivery in malaria infected red blood cells
- Abstract
- 8.1 What is the mechanism of action of antimalarial drugs?
- 8.2 Drug resistance is the bottleneck to malaria treatment
- 8.3 Targeted drug delivery: need of the hour
- 8.4 Lipid-based drug delivery carriers
- 8.5 Liposomes
- 8.6 Nanolipid carriers
- 8.7 Dendrimers
- 8.8 Solid lipid nanoparticles
- 8.9 Nanoemulsions
- 8.10 Self-microemulsifying drug delivery system
- 8.11 Nanoparticles as drug carriers
- 8.12 Peptides as a drug carrier
- 8.13 Aptamers as drug carriers
- 8.14 Drug-loaded erythrocytes
- 8.15 The viral particle as a delivery vehicle
- References
- Chapter 9. Combination drug delivery approaches for tuberculosis
- Abstract
- 9.1 Introduction
- 9.2 Tuberculosis
- 9.3 Formulations and drug delivery routes for tuberculosis treatment
- 9.4 Alternative approaches for drug delivery in tuberculosis disease
- 9.5 Exploring combinatorial approaches for effective tuberculosis therapies: perspectives and challenges
- 9.6 Conclusion
- Acknowledgments
- References
- Part B: Combination drug delivery approaches against cancer
- Chapter 10. Combination drug delivery approaches for cancer therapy
- Abstract
- 10.1 Introduction
- 10.2 Approaches and advantages of combination drug therapy
- 10.3 The role of nanocarriers in combination drug delivery approaches
- 10.4 Drug delivery approaches for cancer biology
- 10.5 Conclusion and future perspective
- Acknowledgments
- References
- Chapter 11. Prodrug-based drug delivery approaches in cancer combination therapy
- Abstract
- 11.1 Introduction
- 11.2 Prodrugs in cancer therapy
- 11.3 Prodrug activation mechanism
- 11.4 Prodrug and nanotechnological applications
- 11.5 Combination therapy in cancer
- 11.6 Conclusion
- References
- Chapter 12. Combination of anticancer drugs with microRNA as cancer therapeutics
- Abstract
- 12.1 Introduction
- 12.2 MicroRNA as anticancer agent
- 12.3 Combination of microRNA with anticancer agents a novel tool for cancer therapy
- 12.4 Nanoparticle used to deliver cancer therapeutics
- 12.5 Applications in cancer and other diseases
- 12.6 Conclusion
- Acknowledgment
- References
- Chapter 13. Nanotechnology-mediated combinational drug delivery approach for cancer therapy
- Abstract
- 13.1 Introduction
- 13.2 Need for combinational drug therapy
- 13.3 Nanotechnology-driven combinational drug delivery
- 13.4 Nanotechnology-based sequential combination therapy
- 13.5 Conclusion
- Conflict of interest
- Acknowledgment
- References
- Part C: Combination drug delivery approaches challenges and future perspectives
- Chapter 14. Premarket review and postmarket regulation of combination drug products
- Abstract
- 14.1 Introduction
- 14.2 Market regulations
- 14.3 Device-based combination products
- 14.4 Drug-based combination product
- 14.5 Biologic product-based combination product
- 14.6 Preclinical and clinical development and regulations
- 14.7 Good clinical practice
- 14.8 Significant regulatory steps in PMA application process
- 14.9 FDA postmarket safety monitoring
- 14.10 Conclusion
- References
- Chapter 15. Concluding remarks and future perspective of combination drug delivery systems
- Abstract
- 15.1 Introduction
- 15.2 Rationale for combination therapy
- 15.3 Combinations with chemotherapy
- 15.4 Immunotherapy–metabolic therapy
- 15.5 Theranostic NPs based on combination therapy and multimodal imaging
- 15.6 Challenges
- 15.7 Conclusion and future perspectives
- References
- Index
- No. of pages: 436
- Language: English
- Edition: 1
- Published: March 27, 2022
- Imprint: Academic Press
- Paperback ISBN: 9780323858731
- eBook ISBN: 9780323858762
PK
Prashant Kesharwani
Dr. Prashant Kesharwani is assistant professor of Pharmaceutics at Department of Pharmaceutical Sciences, Dr. Harisingh Gour Vishwavidyalaya, Sagar, Madhya Pradesh, India. He has more than 12 years of teaching, research, and industrial experience at international levels from various countries, including the United States, Malaysia, and India. An overarching goal of his current research is the development of nanoengineered drug delivery systems for various diseases. He has more than 350 international publications in well-reputed journals and more than 25 international books (Elsevier). He is a recipient of many research grants from various funding bodies. He is also the recipient of several internationally acclaimed awards, such as “USERN Laureate award”, most prestigious “SERB-Ramanujan Fellowship Award”. He actively participates in outreach and scientific dissemination for the service of the wider community. His Number of citations is = 26779; h-index = 85; i-10 index = 370 (According to google scholar on March 2025). He has more than 30 international publications published in very high impact factor journals (Progress in Polymer Sciences IF 32.063, Molecular Sciences IF 41.444, Progress in Material Sciences IF 48.580, Advanced Materials IF 29.4, Drug Resistance Update IF 22.841 and Material Todays IF 32.072). He has presented many invited talks and oral presentations at prestigious scientific peer-conferences, received international acclaims and awards for research contribution, supervised students/junior researchers and actively participated in outreach and scientific dissemination for the service of the wider community.